Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

Scientists from St. Jude Children's Research Hospital, Seattle Children's and the Children's Oncology Group (COG) have identified novel genetic variations that influence relapse risk in children with ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...

Doha: Sidra Medicine has announced the successful completion of its first pediatric allogeneic hematopoietic stem cell transplantation (HSCT), ...

Meghan Jenkins' son was 2 years old when he was diagnosed with cancer in 2021. His prognosis was grim, but aggressive treatment saved his life.

Acute lymphoblastic leukemia (ALL) manifests as a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and eventually extramedullary sites. While mostly ...

In patients with Ph-positive disease, TKIs should be used continuously, which may lead to toxicities. This must be considered during therapy selection. The optimal duration of TKI maintenance is not ...